Pharmalucence formally CIS-US Inc.
Careers News Resources Contact  
    Company
 
  Manufacturing Capabilities
 
  Facility Details 
 
  Nuclear Medicine Products
 
 
 





Company News
Come See Us
Pharmalucence
Company News



December 27, 2011

Pharmalucence Supplemental New Drug Application (sNDA) for the use of Sulfur Colloid Injection (SCI) in the localization of lymph nodes in melanoma patients has been accepted for review by FDA.

Pharmalucence Supplemental New Drug Application (sNDA) for the use of Sulfur Colloid Injection (SCI) in the localization of lymph nodes in melanoma patients has been accepted for review by FDA.

 





For more information, please contact:
John Felock
Director; Sales, Marketing and Customer Service
1-781-687-1245
jfelock@pharmalucence.com



29 Dunham Road, Billerica, MA 01821 | Telephone: 781-275-7120    © Pharmalucence Inc. All rights reserved.
HOME   |   SITE MAP   |   LEGAL STATEMENT   |   PRIVACY POLICY   |